> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Glaxo’s Blenrep
- URL: https://www.fdaweb.com/regulatory-review-period-for-glaxos-blenrep/
- Published: 2022-07-14T12:00:00.000Z
- Updated: 2026-09-14T17:51:56.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152276

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for GlaxoSmithKline’s Blenrep (belantamab mafodotin-blmf), indicated for treating adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The review period is 2,352 days, of which 2,107 days occurred during the testing phase and 245 days occurred during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14916.pdf?ref=fdaweb.com).